Q2 2025 Management View CEO David Michael Cordani reported, "we delivered $67.2 billion in total revenue and grew adjusted ...

Q2 2025 Management View Joseph R. Nolan, President, CEO & Chairman, reported "great progress halfway through the year, executing our key strategic priorities while maintaining our commitment to being ...

Key Points Non-GAAP EPS was $0.65 for Q2 2025, surpassing estimates by 54.8%. Adjusted EBITDA reached a record $4.64 billion in Q2 2025, This compares with $4.34 billion in the same period of 2024.

Key Points Non-GAAP EPS rose to $0.64, beating the $0.53 non-GAAP estimate and up 42.2% year over year for ENI diluted earnings per share (non-GAAP). Net inflows set a firm record at $13.8 billion, ...

Kimberly-Clark beat Q2 EPS estimates despite a sales miss, lifted by strong productivity and a solid 2025 outlook.

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

In Microsoft’s (MSFT) Q4 2025 earnings report, the company reported that it made $76.4 billion in the quarter, comfortably ...

Apple (AAPL) has released its earnings report for Q3 2025, giving us an in-depth look at how the company performed during the ...

Explore IDACORP's Q2 2025 earnings insights, highlighting EPS guidance increase, customer growth, key investments, and resource planning amid ...